Preventing HIV Infection in Women: Targeting Antiretrovirals to Mucosal Tissues

预防女性艾滋病毒感染:针对粘膜组织的抗逆转录病毒药物

基本信息

  • 批准号:
    8493986
  • 负责人:
  • 金额:
    $ 66.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-07-01 至 2014-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The 2007 UNAIDS report estimated that for each person treated with potent antiretroviral therapy, 4-6 new individuals became infected. Without a foreseeable cure for HIV, prevention measures must control the HIV epidemic and structural/barrier/behavioral methods simply have limited efficacy or applicability. There is a critical need, for coitally-independent dosing strategies which women can initiate and are imperceptible to their partners. It is increasingly clear that antiretroviral pharmacokinetics predict efficacy: using samples from the CAPRISA 004 study, our laboratory demonstrated that subjects who maintained the highest tenofovir concentrations in cervicovaginal fluid (and thus in genital tract tissues) were the least likely to become infected with HIV-1 and HSV2. Although topical formulations such as gels and vaginal rings are being investigated, oral antiretroviral drugs also hold significant promise for prevention. Currently, antiretroviral doses used in prevention studies are those that are FDA-approved for treatment of HIV infection. However, there are no data to confirm that exposures with these standard treatment doses will protect mucosal cells from HIV acquisition, or to inform alternative dosing strategies. We propose a highly significant plan to develop a model for oral antiretroviral prevention strategies. In healthy women volunteers, we will determine the ability of 3 doses of 4 antiretroviral drugs to concentrate in 3 at-risk mucosal surfaces. In explant tissue cultures, the concentration of these drugs, alone and in combination, required to protect tissues exposed to multiple infectious molecular clones will be identified. A new approach to normalizing tissue responses to cell numbers and composition will also be implemented. Once the in vivo tissue pharmacokinetic results and ex vivo target concentration results are known, a mathematical model will be developed to predict the antiretroviral doses/regimen maximally protective at all mucosal surfaces. Finally, a second proof-of-concept study is proposed to dose women with the final antiretroviral regimen and challenge tissue biopsies with HIV to determine risk of infection.
描述(由申请人提供):2007年联合国艾滋病规划署报告估计,每个接受强效抗逆转录病毒治疗的人,有4-6个新感染者。在没有可预见的艾滋病毒治愈方法的情况下,预防措施必须控制艾滋病毒的流行,而结构/屏障/行为方法的效力或适用性有限。有一个关键的需要,为性交独立的剂量策略,妇女可以启动,是察觉不到他们的合作伙伴。越来越清楚的是,抗逆转录病毒药代动力学预测疗效:使用CAPRISA 004研究的样本,我们的实验室证明,在宫颈阴道液(因此在生殖道组织)中保持最高替诺福韦浓度的受试者最不可能感染HIV-1和HSV 2。虽然凝胶和阴道环等局部制剂正在研究中,但口服抗逆转录病毒药物也有很大的预防前景。目前,预防研究中使用的抗逆转录病毒剂量是FDA批准用于治疗HIV感染的剂量。然而,没有数据证实这些标准治疗剂量的暴露将保护粘膜细胞免受HIV感染,或告知替代给药策略。我们提出了一项非常重要的计划,以制定口服抗逆转录病毒预防战略的模式。在健康女性志愿者中,我们将确定3种剂量的4种抗逆转录病毒药物集中在3个风险粘膜表面的能力。在外植体组织培养物中,将确定保护暴露于多种感染性分子克隆的组织所需的这些药物单独和组合的浓度。还将实施一种使组织对细胞数量和组成的反应正常化的新方法。一旦体内组织药代动力学结果和离体靶浓度结果已知,将开发数学模型以预测在所有粘膜表面具有最大保护作用的抗逆转录病毒剂量/方案。最后,第二个概念验证研究建议给妇女服用最终的抗逆转录病毒疗法,并用艾滋病毒挑战组织活检以确定感染风险。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
HIV-1 treatment as prevention: the good, the bad, and the challenges.
  • DOI:
    10.1097/coh.0b013e32834788e7
  • 发表时间:
    2011-07
  • 期刊:
  • 影响因子:
    4.1
  • 作者:
    Smith K;Powers KA;Kashuba AD;Cohen MS
  • 通讯作者:
    Cohen MS
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
  • DOI:
    10.1016/s0140-6736(11)60878-7
  • 发表时间:
    2011-07-16
  • 期刊:
  • 影响因子:
    168.9
  • 作者:
    Karim, Salim S. Abdool;Kashuba, Angela D. M.;Werner, Lise;Karim, Quarraisha Abdool
  • 通讯作者:
    Karim, Quarraisha Abdool
Preexposure prophylaxis for HIV infection among African women.
  • DOI:
    10.1056/nejmoa1202614
  • 发表时间:
    2012-08-02
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Van Damme L;Corneli A;Ahmed K;Agot K;Lombaard J;Kapiga S;Malahleha M;Owino F;Manongi R;Onyango J;Temu L;Monedi MC;Mak'Oketch P;Makanda M;Reblin I;Makatu SE;Saylor L;Kiernan H;Kirkendale S;Wong C;Grant R;Kashuba A;Nanda K;Mandala J;Fransen K;Deese J;Crucitti T;Mastro TD;Taylor D;FEM-PrEP Study Group
  • 通讯作者:
    FEM-PrEP Study Group
Pharmacology of HIV integrase inhibitors.
  • DOI:
    10.1097/coh.0b013e328356e91c
  • 发表时间:
    2012-09
  • 期刊:
  • 影响因子:
    4.1
  • 作者:
    Adams JL;Greener BN;Kashuba AD
  • 通讯作者:
    Kashuba AD
Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Angela D Kashuba其他文献

Angela D Kashuba的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Angela D Kashuba', 18)}}的其他基金

Novel Mass Spectrometry Imaging Methods to Quantify Antiretroviral Adherence
量化抗逆转录病毒依从性的新型质谱成像方法
  • 批准号:
    9040663
  • 财政年份:
    2016
  • 资助金额:
    $ 66.88万
  • 项目类别:
Novel Mass Spectrometry Imaging Methods to Quantify Antiretroviral Adherence
量化抗逆转录病毒依从性的新型质谱成像方法
  • 批准号:
    10260722
  • 财政年份:
    2016
  • 资助金额:
    $ 66.88万
  • 项目类别:
Multi-Species Mechanisms of Drug Bio-distribution in HIV Tissue Reservoirs
HIV组织储库中药物生物分布的多物种机制
  • 批准号:
    9226028
  • 财政年份:
    2014
  • 资助金额:
    $ 66.88万
  • 项目类别:
Multi-Species Mechanisms of Drug Bio-distribution in HIV Tissue Reservoirs
HIV组织储库中药物生物分布的多物种机制
  • 批准号:
    9003024
  • 财政年份:
    2014
  • 资助金额:
    $ 66.88万
  • 项目类别:
Multi-Species Mechanisms of Drug Bio-distribution in HIV Tissue Reservoirs
HIV组织储库中药物生物分布的多物种机制
  • 批准号:
    8706563
  • 财政年份:
    2014
  • 资助金额:
    $ 66.88万
  • 项目类别:
Clinical Pharmacology & Analytical Chemistry Core
临床药理学
  • 批准号:
    8531837
  • 财政年份:
    2013
  • 资助金额:
    $ 66.88万
  • 项目类别:
Clinical Pharmacology & Analytical Chemistry Core
临床药理学
  • 批准号:
    8329990
  • 财政年份:
    2011
  • 资助金额:
    $ 66.88万
  • 项目类别:
Preventing HIV Infection in Women: Targeting Antiretrovirals to Mucosal Tissues
预防女性艾滋病毒感染:针对粘膜组织的抗逆转录病毒药物
  • 批准号:
    8284294
  • 财政年份:
    2011
  • 资助金额:
    $ 66.88万
  • 项目类别:
UPLC-MS/MS to Support Preclinical and Clinical Antiretroviral Pharmacology Studie
UPLC-MS/MS 支持临床前和临床抗逆转录病毒药理学研究
  • 批准号:
    8051351
  • 财政年份:
    2011
  • 资助金额:
    $ 66.88万
  • 项目类别:
Pharmacology Core
药理学核心
  • 批准号:
    8326902
  • 财政年份:
    2011
  • 资助金额:
    $ 66.88万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 66.88万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 66.88万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 66.88万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 66.88万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 66.88万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 66.88万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 66.88万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 66.88万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 66.88万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 66.88万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了